Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
Completed · Phase 1 · Has a placebo group
Conditions studied: Parkinson's Disease, Healthy
In brief
The primary objective of the study is to evaluate the safety and tolerability of a range of single BIIB054 doses, administered as a single intravenous (IV) infusion, in healthy participants and participants with early Parkinson's disease (PD). Secondary objectives of the study are to assess the serum pharmacokinetics (PK) profile of BIIB054 after single-dose administration and to evaluate the immunogenicity of BIIB054 after single-dose administration.
Key facts
- Study ID
- NCT02459886
- Run by
- Biogen
- People needed
- 66
- Starts
- 2015-07-01
- Expected to finish
- 2017-11-20
- Last updated by the study team
- 2019-08-08
Who can join
Age: 40 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Research Site — Washington D.C., District of Columbia, United States
- Research Site — Hallandale, Florida, United States
- Research Site — Oviedo, Florida, United States
- Research Site — Evansville, Indiana, United States
- Research Site — Farmington Hills, Michigan, United States
- Research Site — Durham, North Carolina, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Dallas, Texas, United States
- Research Site — Spokane, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.